Curated News
By: NewsRamp Editorial Staff
August 17, 2026
Regentis Advances GelrinC on Dual Tracks: U.S. Trial Hits 50% Enrollment, European Launch Begins
TLDR
- Regentis surges ahead with 50% enrollment in pivotal GelrinC trial, targeting PMA submission by 2027, outpacing rivals in cartilage repair.
- Regentis advances GelrinC via FDA-approved single-arm trial using historical microfracture control, with manufacturing yield boosted 400% for scalability.
- GelrinC offers a 10-minute, cell-free implant for knee cartilage defects, potentially reducing patient suffering and improving quality of life.
- Regentis' GelrinC, already CE Marked in Europe, begins surgeon training at Humanitas, with a 400% manufacturing yield increase, accelerating market entry.
Impact - Why it Matters
This news matters because it signals progress for a novel, off-the-shelf cartilage repair treatment that could offer a faster, less invasive alternative to current cell-based therapies. If the Phase III trial succeeds, GelrinC could become a standard option for knee cartilage defects, potentially improving patient outcomes and reducing healthcare costs. For investors, the parallel advancement in Europe and the U.S. de-risks the timeline, making Regentis a compelling watch in the medtech space.
Summary
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC cartilage repair platform on parallel tracks in the U.S. and Europe, compressing the timeline between clinical validation and market adoption. The company has passed 50% enrollment in the pivotal Phase III SAGE study, with recruitment completion targeted for Q3 2026 and a PMA submission expected by end of 2027. The FDA has approved a single-arm protocol using a historical microfracture control data package owned by Regentis, and early data from the first 40 patients closely match that control group, suggesting GelrinC's efficacy may align with existing benchmarks.
Meanwhile, in Europe, where GelrinC already holds CE Mark approval, surgeon training has begun at Humanitas Research Hospital in Milan, supported by an expanded clinical site network. A newly approved manufacturing process has increased yield by approximately 400%, addressing supply scalability. GelrinC is a cell-free, off-the-shelf hydrogel implant for focal knee cartilage defects, designed for a 10-minute implantation procedure, unlike traditional cell-based therapies requiring two surgeries. This differentiation positions it as a convenient and potentially cost-effective solution.
Regentis is leveraging its proprietary hydrogel technology to navigate regulatory pathways efficiently, and its parallel approach may serve as a model for other medtech firms. With milestones on the horizon, the company is poised to transform cartilage repair treatment, pending successful trial outcomes and regulatory approvals.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Regentis Advances GelrinC on Dual Tracks: U.S. Trial Hits 50% Enrollment, European Launch Begins
